Insider buying last 90 days
No open-market insider purchases were filed for NBIX in the last 90 days.
From Form 4 filings, dated to when each was filed.
Nov 13 close
Neurocrine Biosciences closed at $168.86 on 9 November 2026, +2.6% on the day. The price sits between the 50-day ($147.51) and 200-day ($148.18) moving averages, inside a 52-week range of $122.14 to $186.12. The GekkoIndex reads 40.5, in the Distribution zone, down 15 points over five sessions. Gekko Fair Value is $249.09, so the price is 32.2% below it.
The next earnings report is due on 10 February 2027, 87 days away. Over the last 8 reports the company beat the earnings estimate 6 times, with an average move of 10% across the report. Seasonally, the next 20 trading days from this point averaged -1.6% over the last 5 years, rising in 3 of them.
20 firms rate the stock: 17 buy, 3 hold and 0 sell, with a consensus target of $207.50. A typical daily move is about 3.4%, and a typical 20-day move about 6.1%. On the swing-trade checklist, 2 items read supportive and 1 reads as a headwind (gekkoindex).
A plain summary of the figures as of the Nov 9, 2026 close.
Neurocrine Biosciences scores 3 supportive, 2 mixed and 0 headwinds across the 5 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
3 supportive2 mixed0 headwinds
Averages disagree
Close $167.40 sits between the 50-day ($148.58) and 200-day ($148.88) averages, or the averages disagree.
See the chart46.6, Neutral
Reading 46.6 is in the Neutral zone.
See the GekkoIndex28.9% below
Price is 28.9% below Gekko Fair Value (more than 5% below).
See fair valueNo data
No insider, Congress or unusual options activity in the window.
See smart moneyReports in 87 days
Next report Feb 10, 2027, 87 days away — outside a typical 20-trading-day hold.
See earnings+2.5% on average
From this point in the calendar, the next 20 trading days averaged +2.5% over 5 years, rising in 4 of them.
See seasonalityA description of current data, not a recommendation. How this page works
Neurocrine Biosciences closed at $167.40 on Nov 13, 2026, +14.0% over the past year, inside a 52-week range of $122.14 to $186.12.
Use the left and right arrow keys to read daily values.
Put NBIX on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Neurocrine Biosciences develops and sells medicines aimed at neurological, endocrine, and psychiatric disorders. Its best-known product is INGREZZA, a treatment for tardive dyskinesia, and the company also markets ONGENTYS for use alongside levodopa therapy in Parkinson's disease, ORILISSA for pain tied to endometriosis, and ORIAHNN, a non-surgical oral option for heavy menstrual bleeding caused by uterine fibroids.
Beyond its marketed treatments, the company runs a pipeline of experimental compounds addressing conditions such as focal epilepsy, rare pediatric epilepsy, essential tremor, major depressive disorder, anhedonia linked to depression, and schizophrenia. It pursues some of this work through licensing and collaboration agreements with other pharmaceutical and biotech organizations, including Heptares Therapeutics, Takeda, Idorsia, Xenon Pharmaceuticals, Voyager Therapeutics, BIAL Portela, Mitsubishi Tanabe Pharma, and AbbVie.
Neurocrine Biosciences was established in 1992 and is headquartered in San Diego, California. Its shares are listed on the NASDAQ under the ticker NBIX.
Neurocrine Biosciences’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 46.6, in the Neutral zone, up 5.6 points over five sessions.
Up 5.6 points over five sessions, from the Distribution zone.
Reading for Nov 13, 2026
| Zone | Readings | 5 days | 20 days |
|---|---|---|---|
| Buying | 33 | +0.9% | +1.5% |
| Accumulation | 240 | +0.2% | +1.2% |
| Neutral (current zone) | 394 | +0.2% | +0.3% |
| Distribution | 24 | −0.9% | +0.4% |
| Selling | 11 | +1.7% | −4.0% |
Average NBIX share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Neutral readings averaged +0.9% over 20 days. Past behaviour doesn’t guarantee future results.
Neutral zone: No clear directional signal. About the five zones →
Neurocrine Biosciences trades 28.9% below Gekko Fair Value of $235.42, so the shares are undervalued on Gekko’s estimate.
Gekko’s own estimate of what Neurocrine Biosciences shares are worth, recalculated every trading day.
$235.42
Gekko Fair Value, Nov 14, 2026
28.9% Undervalued
At the end of Aug 2026 the price was 41.5% below the estimate.
No open-market insider purchases were filed for Neurocrine Biosciences, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
No open-market insider purchases were filed for NBIX in the last 90 days.
From Form 4 filings, dated to when each was filed.
No trades in NBIX were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Neurocrine Biosciences has been buying back its own shares.
From company filings.
0of the funds Gekko tracks hold NBIX.
Neurocrine Biosciences reports on Feb 10, 2027 (87 days away), and beat the EPS estimate in 6 of its last 8 reports.
Feb 10, 2027
87 days away
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Nov 2, 2026 | $3.29 est $1.91 | $1.12B est $1.04B | +12.8% |
| Jul 30, 2026 | $2.36 est $1.88 | $959.0M est $891.2M | −7.7% |
| May 5, 2026 | $1.94 est $1.70 | $814.5M est $768.3M | +9.7% |
| Feb 11, 2026 | $1.88 est $1.80 | $805.5M est $790.5M | −10.6% |
| Oct 28, 2025 | $2.17 est $2.07 | $794.9M est $806.8M | −7.3% |
| Jul 30, 2025 | $1.06 est $0.98 | $687.5M est $746.4M | −4.4% |
| May 5, 2025 | $0.08 est $0.54 | $572.6M est $559.6M | +8.4% |
| Feb 6, 2025 | $1.69 est $1.93 | $627.7M est $629.4M | −18.9% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Analysts’ average 12-month price target for Neurocrine Biosciences is $208.11, +24.3% from the last close, from 20 firms rating the stock in the last 90 days.
Each firm’s latest rating in the last 90 days: 20 firms.
| Date | Firm | Target | vs price |
|---|---|---|---|
| Nov 13 | Morgan Stanley | $191 | +14.1% |
| Nov 3 | Canaccord Genuity | $220 | +31.4% |
| Nov 3 | Morgan Stanley | $185 | +10.5% |
| Nov 3 | Piper Sandler | $215 | +28.4% |
| Nov 3 | Wells Fargo | $200 | +19.5% |
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Over the next 20 trading days from Nov 14, Neurocrine Biosciences averaged +2.5% across the last 5 years, rising in 4 of them.
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | −1.6% | 1 of 5 |
| Next 10 trading days | +0.8% | 4 of 5 |
| Next 15 trading days | +1.9% | 4 of 5 |
| Next 20 trading days | +2.5% | 4 of 5 |
| Next 30 trading days | +4.5% | 3 of 5 |
For scale, NBIX’s typical 20-trading-day move in either direction is about 6.1%.
Neurocrine Biosciences’s market cap is $16.94B, with a P/E ratio of 25.1 and revenue of $3.70B over the last twelve months.
Coverage of Neurocrine Biosciences this week reads positive: 5 positive, 3 neutral and 0 negative headlines.
Neurocrine Biosciences’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| AMGNAmgen | Neutral | 19.9% below |
| GILDGilead Sciences | Neutral | 11.7% above |
| MRNAModerna | Neutral | 21.1% above |
| NTRANatera | Accumulation | 18.6% below |
| IQVIQVIA | Accumulation | 5.0% above |
| UTHRUnited Therapeutics | Neutral | 11.2% below |
A peer links to its own page where one exists.
Neurocrine Biosciences’s market cap is $16.94B at the Nov 13, 2026 close of $167.40, with 101.2M shares outstanding. The shares trade on a P/E ratio of 25.1.
The consensus analyst 12-month price target for Neurocrine Biosciences is $208.11, +24.3% from the last close. Of the 20 firms that rated the stock in the last 90 days, 17 rate it a buy, 3 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
On Gekko’s estimate Neurocrine Biosciences is undervalued: the Nov 13, 2026 close of $167.40 is 28.9% below Gekko Fair Value of $235.42. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
Neurocrine Biosciences is expected to report on Feb 10, 2027 (87 days away). Analysts expect earnings of $2.07 per share on revenue of $1.09B. Neurocrine Biosciences beat the earnings estimate in 6 of its last 8 reports, moving 10% on average across the report.
Neurocrine Biosciences’s 52-week high is $186.12 and its 52-week low is $122.14; it closed at $167.40 on Nov 13, 2026, +14.0% over the past year.
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 3 of the 5 items with data read as supportive (fair value, earnings risk and seasonality), 2 as mixed (trend and gekkoindex). The checklist is a description of current data, not a recommendation.
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,475 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.Type a ticker or company name. Press Esc to close.